Tedizolid is highly bactericidal in the treatment of pulmonary Mycobacterium avium complex disease

A ‘shock and awe’ thioridazine and moxifloxacin combination-based regimen for pulmonary Mycobacterium avium–intracellulare complex disease

(2017) Shashikant Srivastava et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Linezolid as treatment for pulmonary Mycobacterium avium disease

(2017) Devyani Deshpande et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

A novel ceftazidime/avibactam, rifabutin, tedizolid and moxifloxacin (CARTM) regimen for pulmonary Mycobacterium avium disease

(2017) Devyani Deshpande et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Azithromycin Dose To Maximize Efficacy and Suppress Acquired Drug Resistance in Pulmonary Mycobacterium avium Disease

(2016) Devyani Deshpande et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Thioridazine as Chemotherapy for Mycobacterium avium Complex Diseases

(2016) Devyani Deshpande et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Characterization of the haematological profile of 21 days of tedizolid in healthy subjects

(2016) Thomas P. Lodise et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

In VitroActivities of Tedizolid and Linezolid against Gram-Positive Cocci Associated with Acute Bacterial Skin and Skin Structure Infections and Pneumonia

(2015) Ko-Hung Chen et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Pharmacokinetics of Tedizolid in Subjects with Renal or Hepatic Impairment

(2014) S. Flanagan et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Nonclinical and Pharmacokinetic Assessments To Evaluate the Potential of Tedizolid and Linezolid To Affect Mitochondrial Function

(2014) Shawn Flanagan et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Tedizolid Population Pharmacokinetics, Exposure Response, and Target Attainment

(2014) S. Flanagan et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2): a randomised, double-blind, phase 3, non-inferiority trial

(2014) Gregory J Moran et al.   LANCET INFECTIOUS DISEASES

Single- and Multiple-Dose Pharmacokinetics and Absolute Bioavailability of Tedizolid

(2014) Shawn Flanagan et al.   PHARMACOTHERAPY

Tedizolid Phosphate vs Linezolid for Treatment of Acute Bacterial Skin and Skin Structure Infections

(2013) Philippe Prokocimer et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Direct Comparison of Xpert MTB/RIF Assay with Liquid and Solid Mycobacterial Culture for Quantification of Early Bactericidal Activity

(2013) X. A. Kayigire et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Time to positivity in liquid culture predicts colony forming unit counts of Mycobacterium tuberculosis in sputum specimens

(2013) Andreas H. Diacon et al.   TUBERCULOSIS

In VitroActivity and Microbiological Efficacy of Tedizolid (TR-700) against Gram-Positive Clinical Isolates from a Phase 2 Study of Oral Tedizolid Phosphate (TR-701) in Patients with Complicated Skin and Skin Structure Infections

(2012) Philippe Prokocimer et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Pulmonary Disposition of Tedizolid following Administration of Once-Daily Oral 200-Milligram Tedizolid Phosphate in Healthy Adult Volunteers

(2012) Seth T. Housman et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

The Antibiotic Resistance Arrow of Time: Efflux Pump Induction Is a General First Step in the Evolution of Mycobacterial Drug Resistance

(2012) Aurelia M. Schmalstieg et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Moxifloxacin Pharmacokinetics/Pharmacodynamics and Optimal Dose and Susceptibility Breakpoint Identification for Treatment of Disseminated Mycobacterium avium Infection

(2010) D. Deshpande et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Ethambutol Optimal Clinical Dose and Susceptibility Breakpoint Identification by Use of a Novel Pharmacokinetic-Pharmacodynamic Model of Disseminated Intracellular Mycobacterium avium

(2010) D. Deshpande et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY